Presentation and management of a stage Ia lung cancer patient with a paraneoplastic factor VIII inhibitor.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 16368409.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Acquired inhibitors to clotting factors most commonly involve factor VIII and are associated with autoimmune disease. Factor VIII inhibitors can cause severe spontaneous and iatrogenic bleeding that is difficult to manage. Factor VIII inhibitors are rarely associated with solid tumors and only three cases of adenocarcinoma of the lung have been reported. This report describes the multidisciplinary management of a factor VIII inhibitor-producing stage Ia lung adenocarcinoma that ultimately resulted in complete resectability.
Medical subject headings
- Adenocarcinoma
- Autoantibodies
- Autoimmune Diseases
- Blood Coagulation Factors
- Blood Loss, Surgical
- Factor VIII
- Hemorrhage
- Lung Neoplasms
- Paraneoplastic Syndromes
- Pneumonectomy